CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A
- 1st Edition, Volume 208 - September 11, 2024
- Imprint: Academic Press
- Editor: Vijay Singh
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 3 1 5 8 8 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 1 5 8 9 - 3
CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key te… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source.
This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
- Updares on CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease and fungal disease
- Discusses stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders
- Includes commentary on CRISPR in autoimmune and blood disorders
Students, researchers, clinicians, entrepreneurs, and stakeholders
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Chapter One: An overview and potential of CRISPR-Cas systems for genome editing
- Abstract
- Abbreviations
- 1 Introduction
- 2 Zinc finger nucleases (ZFNs)
- 3 Transcription activator-like effector nucleases (TALENs)
- 4 CRISPR-Cas systems
- 5 Evolution of CRISPR-Cas system
- 6 Mechanism of CRISPR-Cas systems
- 7 Types of CRISPR-Cas systems
- 8 Applications of CRISPR-Cas systems
- 9 Conclusion and future challenges
- Acknowledgement
- References
- Chapter Two: Advances in CRISPR-Cas systems for human bacterial disease
- Abstract
- 1 Introduction
- 2 Application of CRISPR-Cas system in human bacterial diseases
- 3 CRISPR-Cas systems to combat antimicrobial resistance
- 4 CRISPR in precision antibacterials
- 5 CRISPR in ESKAPE pathogens
- 6 CRISPR in tuberculosis
- 7 CRISPR in pathogen detection
- 8 Ethical and regulatory considerations
- 9 Conclusion and future perspectives
- References
- Chapter Three: CRISPR-Cas based genome editing for eradication of human viruses
- Abstract
- Abbreviations
- 1 Introduction
- 2 Exploring CRISPR-Cas systems for genome editing of human viruses
- 3 Hepatitis B virus
- 4 Human papillomavirus
- 5 Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2)
- 6 Conclusion and future remarks
- Acknowledgments
- References
- Chapter Four: Advances in CRISPR-Cas systems for gut microbiome
- Abstract
- 1 Introduction
- 2 CRISPR-Cas for probiotic development
- 3 CRISPR-Cas for microbiome diagnostics
- 4 CRISPR-Cas for pathogen targeting
- 5 CRISPR-Cas for microbiome engineering
- 6 Ethical and regulatory issues related to use of CRISPR-Cas
- 7 Conclusion and future perspectives
- References
- Chapter Five: Advances in CRISPR-Cas systems for fungal infections
- Abstract
- Abbreviations
- 1 Introduction
- 2 Common methods for changing the genes of fungi
- 3 Utilization of CRISPR/Cas systems in fungal genetic engineering
- 4 Current constraints and future potential of CRISPR/Cas-mediated fungi genome engineering
- 5 Conclusion
- References
- Chapter Six: Recent development in CRISPR-Cas systems for human protozoan diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Plasmodium
- 3 Leishmania
- 4 Trypanosoma
- 5 Concluding remarks and future aspects
- Acknowledgements
- References
- Chapter Seven: Advances in CRISPR/Cas systems-based cell and gene therapy
- Abstract
- 1 Introduction
- 2 Delivery formats
- 3 Delivery methods
- 4 Engineered systems
- 5 Clinical applications
- 6 Conclusion and future directions
- References
- Chapter Eight: Advances in CRISPR-Cas systems for epigenetics
- Abstract
- Abbreviations
- 1 Introduction
- 2 Manipulation of epigenetics
- 3 CRISPR-Cas protocols and strategies
- 4 CRISPR-Cas for DNA methylation
- 5 CRISPR-Cas for histone modification
- 6 CRISPR-Cas for RNA targeting
- 7 Pharmacological and toxicological aspects of CRISPR-Cas
- 8 Conclusion and future perspectives
- References
- Chapter Nine: Current progress in CRISPR–Cas systems for cancer
- Abstract
- Abbreviations
- 1 Introduction
- 2 Basics of cancer biology
- 3 CRISPR-Cas techniques for cancer genome editing
- 4 CRISPR-based screening for cancer therapeutics
- 5 Types of CRISPR-based screening for cancer therapeutics
- 6 Modes of CRISPR-based screening for cancer therapeutics
- 7 Future perspectives for CRISPR-Cas system in cancer
- 8 Conclusion
- References
- Chapter Ten: Current progress in CRISPR-Cas systems for autoimmune diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Explanation of the fundamentals of CRISPR-Cas systems and their method of action
- 3 Overview of CRISPR components (e.g., Cas proteins, guide RNA)
- 4 Historical background and key milestones in CRISPR research
- 5 CRISPR/Cas9 and rheumatoid arthritis
- 6 CRISPR/Cas9 and systemic lupus erythematosus (lupus)
- 7 CRISPR/Cas9 and multiple sclerosis (MS)
- 8 CRISPR/Cas9 and type 1 diabetes
- 9 CRISPR/Cas9 and psoriasis
- 10 CRISPR/Cas9 and inflammatory bowel disease (IBD)
- 11 CRISPR/Cas9 and Hashimoto’s Thyroiditis
- 12 Integrative research on autoimmune diseases using CRISPR-Cas systems
- 13 Recent advancements in CRISPR-based therapies
- 14 Challenges and limitations
- 15 Future directions and opportunities
- 16 Conclusion
- References
- Chapter Eleven: Advances in CRISPR-Cas systems for blood cancer
- Abstract
- Abbreviations
- 1 Genetic landscape of blood cancers
- 2 Exploring CRISPR-Cas techniques
- 3 CRISPR-Cas applications in the treatment of haematological cancers
- 4 Clinical trials and therapeutic outcomes
- 5 Overcoming challenges in CRISPR-Cas editing
- 6 Ethical and regulatory considerations
- 7 Future perspectives and conclusion
- Acknowledgements
- References
- Index
- Edition: 1
- Volume: 208
- Published: September 11, 2024
- Imprint: Academic Press
- No. of pages: 308
- Language: English
- Hardback ISBN: 9780443315886
- eBook ISBN: 9780443315893
VS
Vijay Singh
Dr Vijai Singh serves as Professor and Dean (Research & Innovation) at School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. He was an Associate Professor in the Department of Biosciences, School of Sciences, Indrashil University, Rajpur, Mehsana, Gujarat, India. Prior this this, he was an Assistant Professor in the Department of Biological Sciences and Biotechnology at the Institute of Advanced Research, Gandhinagar, India and also an Assistant Professor in the Department of Biotechnology at the Invertis University, Bareilly, India. Prior to that, he was a Postdoctoral Fellow in the Synthetic Biology Group at the Institute of Systems and Synthetic Biology, Paris, France and School of Energy & Chemical Engineering at the Ulsan National Institute of Science and Technology, Ulsan, South Korea. He received his Ph.D. in Biotechnology from the National Bureau of Fish Genetic Resources, Uttar Pradesh Technical University, Lucknow, India with a research focus on the development of molecular and immunoassays for diagnosis of Aeromonas hydrophila. His research interests are focused on building novel biosynthetic pathways for production of medically and industrially important biomolecules. Additionally, his laboratory is working on CRISPR-Cas9 tools for genome editing. He has more than 11 years of research and teaching experience in synthetic biology, metabolic engineering, bioinformatics, microbiology, and industrial microbiology. He has published 100 articles, 70 book chapters, 17 books and 3 patents. He serves as an associate editor, editorial board member, and reviewer of several peer-reviewed journals. He is also a member of the Board of Study and Academic Council of Indrashil University and is the Member Secretary of the Institutional Biosafety Committee (IBSC) at the same University.
Affiliations and expertise
Department of Biosciences, School of Science, Indrashil University, Rajpur, Mehsana, IndiaRead CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A on ScienceDirect